Prof. Dr. Inamul Hasan Madar | Medicine | Yenepoya Universtiy |India
Dr. Inamul Hasan Madar is a distinguished researcher and educator in the field of biochemistry with a specialization in oncology proteogenomics. He earned his PhD from Korea University, a globally ranked institution, and has since developed extensive expertise in cancer genomics, multiomics integration, and bioinformatics. With a strong commitment to advancing medical research, Dr. Madar has served as an adjunct faculty at Saveetha Medical College (SIMATS), where he has mentored PhD, MD, MBBS, and MSc students in cutting-edge biomedical sciences. His international research experience includes appointments at Korea University and Hanyang University in South Korea, where he contributed to high-impact oncology projects. As Director and Lead of Canary Oncoceutics India, he has bridged the gap between research and industry by leading innovative onco-therapeutic initiatives. Widely published in top-tier journals, Dr. Madar has also served as a reviewer for international journals and as a member of prestigious scientific societies worldwide.
Author profile
Orcid
Education
Dr. Madar’s academic journey reflects a deep pursuit of excellence in biomedical sciences. He earned his PhD in Biochemistry, specializing in Onco-Proteogenomics, from Korea University, Seoul, ranked among the top global universities. His doctoral work focused on proteogenomic profiling and cancer biomarker discovery, positioning him at the forefront of precision oncology. Before this, he pursued advanced training in bioinformatics, molecular biology, and proteomics, equipping him with multidisciplinary skills to tackle complex biomedical challenges. His postgraduate education emphasized molecular diagnostics and computational approaches, while his undergraduate studies laid the foundation in biochemistry and clinical applications. Dr. Madar has also completed specialized training programs in next-generation sequencing (NGS), computational modeling, molecular docking, and drug discovery pipelines. Furthermore, he has been actively engaged in faculty development programs, including pedagogy training for undergraduate teaching in life sciences and biotechnology. This comprehensive educational background underscores his ability to combine research innovation with academic excellence.
Experience
Dr. Madar’s professional experience spans academia, research, and industry. He currently serves as Adjunct Faculty at Saveetha Medical College, SIMATS, where he mentors MBBS, MD, MSc, MPhil, and PhD students in research methodologies, cancer biology, and bioinformatics. He is also Director and Lead (Marketing) at Canary Oncoceutics India, overseeing translational oncology research and innovation in oncoceutical product development. Internationally, he worked as a Visiting Scientist at Korea University, specializing in proteogenomics, and as a Researcher at Hanyang University, Seoul, in bioengineering. In India, his previous roles include Scientist & Course Coordinator at Biocuration, where he designed genomics and drug development modules, and Junior Scientist at iPro Technologies. He has also contributed as a guest lecturer at Bharathidasan University, training future biochemists. His expertise extends to designing computational pipelines, analyzing multiomics datasets, and leading cross-disciplinary projects that bridge laboratory science and clinical application, particularly in cancer therapeutics and biomarker discovery.
Awards and Honors
Dr. Inamul Hasan Madar has received widespread recognition for his contributions to biomedical research and education. His publications in high-impact journals such as Nature Cancer, Oncotarget, Briefings in Bioinformatics, and Molecular Cancer have positioned him among leading voices in proteogenomics and cancer research. He has served as a peer reviewer for several prestigious journals, including Nature’s Scientific Reports, Frontiers in Oncology, BMC Medical Genomics, and Journal of Translational Medicine. He has been actively involved in international professional societies, including the American Association of Cancer Research (AACR), American Society for Biochemistry and Molecular Biology (ASBMB), International Society of Computational Biology (ISCB), and South African and Korean Mass Spectrometry Societies. His leadership roles include serving as Vice President of ISCB-RSG India, demonstrating his dedication to strengthening scientific networks. He has also mentored numerous graduate and medical students, guiding them to publish impactful research, file patents, and develop translational medical applications.
Research Focus
Dr. Madar’s research focus lies at the intersection of cancer genomics, proteogenomics, and computational biology. He specializes in integrating multiomics datasets to identify novel biomarkers and therapeutic targets for treatment-resistant cancers, particularly cervical, prostate, and oral squamous cell carcinoma. His expertise in next-generation sequencing (RNA-Seq, Exome-Seq) and bioinformatics has enabled him to develop innovative pipelines for cancer biomarker discovery, molecular subtyping, and clinical variant interpretation. Beyond oncology, he has contributed to research in neurobiology, metabolic disorders, cardiovascular protection, and bioactive peptides against diabetes and obesity. His translational approach emphasizes the “bench-to-bedside” concept, applying computational models and molecular profiling to guide precision medicine strategies. Dr. Madar has also explored theranostic targets, signaling networks, and novel oncoceutical formulations. His interdisciplinary collaborations with international research groups have advanced drug design, CAR-T therapy applications, and personalized treatment strategies, positioning him as a pioneer in cancer research and translational medicine.
Publications
-
Correction to: Proteogenomic characterization of molecular and cellular targets for treatment-resistant cervical cancers.
-
Molecular analysis of HPV16 and HPV18 oncogenes in oral squamous cell carcinoma.
-
Proteogenomic characterization of treatment-resistant subtypes in cervical cancers.
-
Theranostic Target NSUN2 uncovered with systematic assembly of 805 datasets.
-
Unravelling the phosphoregulatory network of PKC-delta (PKC-δ).
-
BDNF-TrkB signalling: A neurotrophic pathway to cardiovascular protection.
-
Physiological activities of bioactive peptides against diabetes and obesity.
-
SGLT2 inhibitors as dual therapeutic targets for cardiovascular and renal health.
-
Biobased nanomaterials and rhizobacteria for sustainable plant growth.
-
CAR-T therapy in oral squamous cell carcinoma: Current innovations and future prospects.
Conclusion
Dr. Inamul Hasan Madar exemplifies excellence in translational medicine, combining cutting-edge cancer research with dedicated academic mentorship. His impactful publications, international collaborations, and leadership in oncology research position him as a transformative figure in biomedical sciences. Through his expertise in proteogenomics and bioinformatics, he continues to advance precision medicine while inspiring the next generation of medical researchers.